In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Crude awakening: Kapoor’s renewable-material protest art installed on Shell gas platform
In the North Sea, protest art made by Anish Kapoor, using renewable materials such as used coffee grounds and beetroot powder, has been installed...
Tiny Vinyl to release tiny, biobased PVC records
In the US, a startup called Tiny Vinyl has created cute, mini, vinyl records out of bio-attributed polyvinyl chloride. The 4-inch mini singles play...
Fun with Fungi: Japanese designers create mycelium block-growing kit
In Japan, designers have created a biomaterial kit for growing toy blocks out mycelium. Dubbed MYMORI, the kit includes block molds and a mycelium...